Quick Facts
FONT-SIZE Plus   Neg
Share SHARE
mail  E-MAIL

ChemoCentryx Reports Publication Of Positive Phase 2 Data With CCX354

RELATED NEWS
Trade CCXI now with 
6/8/2012 7:13 AM ET

ChemoCentryx Inc. (CCXI: Quote) announced the peer-reviewed publication of positive data from its Phase 2 CARAT-2 study for CCX354, a potent and selective, orally-administered inhibitor of CCR1, a chemokine receptor that drives the recruitment of inflammatory cells into the joints of patients with rheumatoid arthritis or RA. The findings showed that CCX354 was generally well tolerated by patients with RA.

Measurement of evidence of clinical activity included the ACR20 response at Week 12 in patients who met trial inclusion criteria at the start of dosing: The response was 56% in patients receiving 200 mg CCX354 once daily, versus 44% in patients receiving 100 mg twice daily and 30% in patients receiving placebo. ACR20 is a standard measure of improvement in tender and swollen joint counts. The difference between 200 mg once daily and placebo was statistically significant.

Also, the data indicated that CCX354 treatment reduced markers of bone turnover, supporting the previously documented role of CCR1 in osteoclast maturation and migration.

"Results from the CARAT-2 study have demonstrated clinical proof-of-concept of CCR1 inhibition in the treatment of RA," stated Thomas Schall, President and Chief Executive of ChemoCentryx.

Register
To receive FREE breaking news email alerts for ChemoCentryx Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Justin Moore has been named Humanitarian of the Year by by the Armed Forces Foundation. Moore received the award alongside Big Machine Label Group President/CEO Scott Borchetta for their service and commitment to the morale and welfare of military families through the Crown Royal "Your Hero's Name Here" contest. International Business Machines Corp. said Wednesday after the markets closed that its first quarter profit fell 21% from last year, hurt by lower revenue as well as a hefty workforce rebalancing charge. The company's quarterly earnings per share, excluding items, came in line with analysts' expectations, but its quarterly revenue fell short of analysts' forecast. Stocks moved sharply higher over the course of the trading day on Wednesday, further offsetting the steep losses posted late last week. The markets benefited from a positive reaction to the latest earnings news as well as remarks by Federal Reserve Chairman Janet Yellen. The major averages saw further upside going into the close, ending the session at their best levels of the day.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.